

# TheraPEAK 293-GT<sup>®</sup> Media System

**Lonza**  
Specialized Modalities



## Improve viral titers in your AAV program with our flexible media system


Off-the-shelf, complete viral production kits are often incomplete in meeting the needs of your specialized gene therapy program. The TheraPEAK 293-GT<sup>®</sup> Media System (growth medium with included AAV supplement) is a drop-in-ready solution to support high-yield AAV production in suspension HEK293 cells across a variety of transfection reagents, cell lines, and plasmid backbones. This greater flexibility in process optimization accelerates delivery of high-quality lead candidates.

### Features and benefits


- Chemically defined to support consistency, regulatory compliance, and supply security with no animal origin components; ready for RUO or GMP use
- Transfection supplement capable of as much as a ~3x increase in AAV titers when used with commercially available enhancers
- Flexible across multiple HEK293 cell lines with strong growth and cell viability

- Supports favorable full-to-empty capsid ratios to maximize downstream efficiency
- Easy integration into your existing workflow – works with multiple transfection reagents and enhancers


With its optimized composition and broad applicability, the TheraPEAK 293-GT<sup>®</sup> Media System offers a powerful solution for researchers and manufacturers seeking efficiency, reproducibility, and industry-relevant outcomes. This flexible media system can easily integrate with existing workflows, boosting functional AAV yield without disrupting established transfection protocols.




**Figure 1.** Performance of TheraPEAK 293-GT<sup>®</sup> Media System across four HEK293 suspension cell lines. Above data is comparable to growth and viability of cell lines when nurtured in their cloning media, demonstrating robust growth.



**Figure 2.** Addition of TheraPEAK 293-GT<sup>®</sup> AAV Supplement during transfection supports increased AAV titer (>1e12 Vg/mL) across multiple serotypes as compared to a commercial enhancer alone.



**Figure 3.** TheraPEAK 293-GT<sup>®</sup> Media System works across multiple transfection reagents and viral serotypes. TheraPEAK 293-GT<sup>®</sup> generated viral yields superior to a leading competitor AAV system when screening two commercially available transfection reagents.



**Figure 4.** TheraPEAK 293-GT<sup>®</sup> Media System delivers a high percentage of full capsids across multiple transfection reagents, enhancers, and viral serotypes, making it ideal for commercial AAV production

### Product information

Catalog no.	Description	Size and packaging
BP18-971	TheraPEAK 293-GT <sup>®</sup> Media System (includes TheraPEAK 293-GT <sup>®</sup> Medium and AAV Supplement)	1 L bottle (medium) and 50 mL bottle (supplement)

## Contact us

### North America

Customer Service: +1 800 638 8174 (toll free)  
 order.us@lonza.com  
 Scientific Support: +1 800 521 0390 (toll free)  
 scientific.support@lonza.com

### Europe

Customer Service: +32 87 321 611  
 order.europe@lonza.com  
 Scientific Support: +49 221 99199 400  
 scientific.support.eu@lonza.com

### International

Contact your local Lonza distributor  
 Customer Service: +1 301 898 7025  
 scientific.support@lonza.com

Lonza Walkersville, Inc. – Walkersville, MD 21793

Learn more.



This product is not for human or animal *in vivo* or diagnostic use, including use as a diluent or as an excipient. This product is suitable for GMP manufacturing. All TheraPEAK 293-GT<sup>®</sup> Products are produced according to applicable GMP standards and follow the USP/EP guidance for cell and gene therapy raw materials. Lonza Group Ltd. and its affiliates (collectively and individually, "Lonza") make efforts to include accurate and up-to-date information. However, Lonza makes no representations or warranties, express or implied, including as to accuracy or completeness of information. All trademarks belong to Lonza, and are registered in the USA, EU and/or CH, or used in common law, or belong to third-party owners and are used for only informational purposes. All third-party copyrights have been reproduced with permission from their owners. The user bears the sole responsibility for determining the existence of any third-party rights and obtaining any necessary licenses and approvals. For more information, including regarding legal disclaimers, Lonza's intellectual property rights, and how Lonza collects, uses and protects personal information: [www.lonza.com/legal](http://www.lonza.com/legal), <https://www.lonza.com/about-us/strategy/intellectual-property> and [www.lonza.com/privacy](http://www.lonza.com/privacy).